The Muscular Dystrophy Association (MDA) recognizes today’s decision by the U.S. District Court for the District of ...

Washington, D.C – Monday, February 10, 2025 – Today, in response to the National Institutes of Health’s proposal to limit indirect costs to 15% of all grants, Donald S. Wood, PhD, President and CEO of ...

NEW YORK – Monday, October 28, 2024 – The Muscular Dystrophy Association and the Players Trust, the charitable arm of the Major League Baseball Players Association, are thrilled to announce that ...

More than 5,500 people in the St. Louis area are helped by the MDA each year. ST. LOUIS — 5 On Your Side’s annual telethon benefitting the Muscular Dystrophy Association is back Labor Day weekend.

MDA Summer Camp wouldn’t be possible without people like you. Each summer, hundreds of volunteers serve as counselors and medical team members during weeklong, overnight Summer Camp programs to help ...

The gene that’s defective in oculopharyngeal muscular dystrophy (OPMD) was discovered in 1998. It carries instructions for a polyadenylate binding protein (PABPN1) that’s normally present in the cell ...

Join MDA for an informative webinar focused on navigating changes to state and federal benefits. Whether you're a patient, caregiver, or advocate, this webinar will offer valuable insights, resources, ...

MDA is the #1 health nonprofit advancing research, care and advocacy for people living with muscular dystrophy, ALS, and related neuromuscular diseases.

You don’t have to navigate your neuromuscular disease journey alone. As a member of the MDA Community, one of the many ways you can connect with others and share your personal story is by joining an ...

MDA is proud to offer the Durable Medical Equipment (DME) Grant to help children and adults living with neuromuscular diseases get the equipment they need to live more independently and comfortably.

New York, March 10, 2025 – The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab ...